(firstQuint)A Study of FluzoparibSHR-3162in BRCA1/2-mutant Relapsed Ovarian Cancer.

 Fluzoparib (SHR-3162) is an orally available, small molecule inhibitor of poly-adenosine diphosphate [ADP] ribose polymerase (PARP) 1/2 being developed for treatment of BRCA1/2-mutant solid tumor.

 The tolerability, safety and PK of fluzoparib has been evaluated in Phase 1 study.

 An oral formulation is the focus of current development efforts.

.

 A Study of FluzoparibSHR-3162in BRCA1/2-mutant Relapsed Ovarian Cancer@highlight

This is a multicenter, open-label study to evluate the efficacy and safety of a novel PARP 1/2 inhibitor fluzoparib (SHR-3162)in BRCA1/2-mutant Relapsed Ovarian Cancer.

